Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD20 Dual-CAR-T for B-cell Lymphoma
NCT04260932Phase 1Terminated
- Sponsor
- Lu Daopei Hospital
- Start
- Mar 2020
- Primary completion
- May 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD20 dual CAR-T in B cell lymphoma, sponsored by Lu Daopei Hospital. Primary endpoints: Percentage of participants with adverse events at 6 months and Objective remission rate at 6 months. Started Mar 2020; status: terminated.
02
Drugs
CD19/CD20 dual CAR-T
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04260932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260932.